FDA recall record

Sandoz Candesartan Cilexetil Tablets, 16 mg, a) 30 count (NDC 00781-5938-31) and b) 90 count recall — FDA D-0659-2016

Failed Impurities/Degradation Specifications; 9 month stability timepoint

Class IIIclassification
D-0659-2016official record ID
Feb 17, 2016report date

Recall record at a glance

Official recordD-0659-2016
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmSandoz Inc.
Report dateFeb 17, 2016
Recall initiation dateDec 31, 2015
Quantity277,267 bottles
LocationPrinceton, NJ, United States

Official product description

Candesartan Cilexetil Tablets, 16 mg, a) 30 count (NDC 00781-5938-31) and b) 90 count (NDC 00781-5938-92) bottles, Rx Only, Manufactured by Mylan Laboratories Limited Hyderabad 500 034, India for Sandoz Inc. Princeton, NJ 08540

Why the product was recalled

Failed Impurities/Degradation Specifications; 9 month stability timepoint

Distribution information

Nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.